Navigation Links
United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
Date:10/10/2011

SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.  Based on the support from this contract, approximately 20 jobs will be created at Unither Virology's headquarters in Silver Spring, Maryland, with additional jobs created at subcontractor organizations.

"I'm pleased with the development of our broad-spectrum antiviral program, which is in the preclinical stage," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The overall objective for this partnership with NIH is to develop a safe and orally available broad-spectrum antiviral drug to treat viruses such as dengue and influenza.  Dengue is a painful mosquito-borne tropical fever suffered by millions of patients worldwide each year, and this program may help provide a path to treatment.  It is also rewarding to see how our industry generates dozens of jobs when the science data justify expanding a program to its next stage of growth."

The contract provides for up to approximately $45 million in total funding over five years.  The base period of 42 months includes approximately $10.6 million in funding.  The remaining funds are allocated to eight milestone-based options.  Funding will support the development of a candidate compound through preclinical safety and efficacy studies toward potential clinical trials against dengue, as well as preclinical studies to develop additional data against influenza.

'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
2. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
3. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
6. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
7. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
8. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
9. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
10. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
11. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 3.75% Convertible Senior Notes due May 1, 2015 ... $1,000 principal amount or approximately $5.72 per share, effective March 3, ... is adjusted in connection with the regular quarterly dividend of ... who own shares of PDL on March 5, 2015, the record ...
(Date:3/4/2015)... The UPMC Center for Health Security today announced the ... in Biosecurity Initiative (ELBI). As part of our commitment ... UPMC has selected 28 US and international emerging leaders ... biological science, medicine, policy, the military, think tanks and ... and support of the Defense Threat Reduction Agency in ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... 2011 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ... systems, announced today that its work entitled "Evaluation of ... in Healthy Volunteers" will be presented at the Eleventh ... held in San Francisco, California. "The selection ...
... N.J., Oct. 25, 2011 Quest Diagnostics Incorporated (NYSE: ... has begun the process of identifying a successor to Surya ... Board of Directors has formed a search committee, engaged a ... internal candidates. Dr. Mohapatra has agreed to ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... update on operations and disclosed the outcome of a ... by management and AMT,s Board of Directors that enables ... therapy development. The CHMP,s recent opinion, while not approving ...
Cached Biology Technology:Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2Quest Diagnostics Initiates CEO Succession Process 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... light," winners are able to stop, and take off ... reveals that a similar race goes on in our ... "The research provides new insights into how the brain ... with attention deficit and hyperactivity disorder," study co-author Jeffrey ...
... owner than a lost cat, according to two new studies. , In ... lost dogs were found, compared to just 53 percent of lost cats. ... by a call or visit to an animal shelter. More than one ... or identification tag at the time of its disappearance. , "The ...
... M.D., Professor of Medicine and Pharmacology at the University ... studied about 265 twin pairs over the past few ... , "By studying many traits and genes, we have ... , Studying genetic variations in twins provides scientists with ...
Cached Biology News:Racing neurons control whether we stop or go 2Racing neurons control whether we stop or go 3Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: